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An increasing number of oncology patients are seen by
cardiologists every day, and a dilemma facing both the
cardiologist and the oncologist is how to predict risk of
cardiac toxicity. Efﬁcacious therapies targeting malignant
cancers are now recognized as potentially harmful for the
heart. Many of the novel cancer therapies include kinase
inhibitors (KIs). Protein kinases are enzymes that add
a phosphate to proteins and regulate critical cell functions
such as cell growth, death, and survival. Therapeutic tar-
geting of kinases expressed in cancer, or the cancer kinome,
with either humanized monoclonal antibodies or with KIs
has revolutionized the treatment of many cancers, leading to
improvements in patient survival and prognosis.See page 1011In this issue of the Journal, Pﬁster et al. (1) insightfully
activate a kinase and show how it is beneﬁcial and protective
for the heart. This approach is insightful because the cancer
literature has shown therapeutic efﬁcacy in inhibiting this
very kinase to treat cancer. The increasing knowledge of the
cancer and the heart kinomes allow us to better understand
and prevent cardiotoxicity related to cancer therapies as well
as to identify novel molecular targets to treat heart disease.
The study by Pﬁster et al. (1) joins the evolving ﬁeld of
cardio-oncology research by exploring the role of FMS-like
tyrosine kinase (FLT3) and FLT3 ligand (FL) signaling in
the heart. It found that intramyocardial injection of FL,
following the ligation of the left anterior descending artery in
mice, was associated with reduced infarct size, improved left
ventricular function and decreased number of apoptotic*Editorials published in the Journal of the American College of Cardiology reﬂect the
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authors propose that activation of FLT3 signaling may serve
as an internal, antiapoptotic, and protective system in the
heart that may be particularly relevant in the setting of
oxidative stress and myocardial injury. They also speculate
that inhibition of FLT3 signaling, such as caused by the KIs,
may result in a loss of this critical cytoprotection and lead to
cardiomyocyte death.
FLT3 and FL are well-known targets in the armamen-
tarium of anticancer therapeutics. The activating mutation
in this tyrosine kinase receptor can be detected in up to 30%
of acute myeloid leukemias and is associated with a distinctly
poor clinical outcome for patients (2). Since the 1996
discovery of the importance of FLT3 mutation in leuke-
mogenesis, many small molecules have been tested in an
attempt to inhibit FLT3 signaling (3). Some of the KIs in
currently open clinical trials in patients with malignancies
carrying mutated FLT3, include crenolanib, PKC412
(midostaurin), CEP-701 (lestaurtinib), and AC220 (qui-
zartinib), as well as more widely used multitargeted tyrosine
KIs sunitinib and sorafenib. Both sunitinib and sorafenib
have been associated with cardiac adverse effects ranging
from hypertension and acute coronary syndrome to left
ventricular dysfunction and heart failure. It is important to
note that these 2 KIs, in addition to FLT3, inhibit a large
a number of distinct kinases and recent studies have sug-
gested that their inhibition of the vascular endothelial
growth factor–signaling pathway may be the key underlying
mechanism leading to cardiotoxic phenomena (4). However,
little is known regarding if and what role different KIs’
targets may have in cardiac cellular homeostasis.
Kinases have been a long-time “darling” of cancer
researchers. The clinical success of imatinib, the ﬁrst
approved inhibitor of BCR-Abl kinase mutated in chronic
myeloid leukemia, was followed by an explosion of onco-
logical agents designed to inhibit different, frequently more
ubiquitously expressed kinases (5). With the growth of
several kinase-targeted oncological therapies, unexpected
and serious cardiotoxic events, including left ventricular
dysfunction and heart failure, have been observed (6). These
reports rapidly highlighted our limited understanding of the
heart kinome and the urgent need for investigations of the
vulnerability of the heart in the setting of kinase-targeted
cancer treatment.
How do the new ﬁndings by Pﬁster et al. (1) translate into
clinical questions of cardio-oncology? The ﬁrst and most
obvious question is the concern regarding potential car-
diotoxicity of FLT3-targeted cancer therapeutics. If FLT3
activation is beneﬁcial and important for cardiomyocyte
survival, then blockade of this signaling pathway may lead to
cardiomyocyte injury and death, resulting in clinical cardiac
dysfunction. The murine model of left anterior descending
artery ligation, used in this study, does not help us answer
the question if clinical comorbidities, such as hypertension,
or previous myocardial infarction (frequently encountered in
patients with cancer) may represent conditions in which
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1021FLT3 activation of the survival chain may be critically
important. Identifying which patients may be at increased
risk for cardiotoxicity with FLT3-targeted therapeutics
remains a question for future studies. For the interested
reader, the recent state-of-the-art paper by Lal et al. (7)
summarizes the need for improved pre-clinical models and
outlines complementary approaches that may allow us to
predict risk of cardiotoxicity related to the use of molecularly
targeted cancer therapy.
Second, a frequent clinical cardio-oncology question is
which speciﬁc KI or a combination of KIs with or without
other cancer therapies may result in clinical cardiotoxicity.
Pﬁster et al. (1) did not test the effects of KIs and inhibition
of endogenous FLT3 signaling in their animal model. Thus,
the relevance of these ﬁndings for clinically approved or
investigated FLT3-targeting cancer therapeutics need
further study. By providing new evidence that FLT3 inhi-
bition may lead to cardiac injury, this study builds a strong
rationale for investigation and monitoring of cardiac func-
tion in animal models as well as in patients with cancer
receiving KIs that target FLT3 pathways.
An important technical limitation of this study (1) is that
exogenous FL may not accurately reﬂect the role of
endogenous FLT3 signaling in the heart. Animal models
with cardiomyocyte-targeted deletion or inhibition of FLT3
and its downstream mediators will be needed to conﬁrm the
proposed role of FLT3 signaling within the heart kinome.
This approach has been successfully used in studying the role
of other cancer treatment-targeted kinases in the heart (4)
and has opened an important area of research that
continues to grow.
On the ﬂip side of the coin is the perspective of use of
FLT3 as a potential therapeutic target in cardiac ischemia.
Pﬁster et al. (1) demonstrate beneﬁcial effects of FLT3
signaling in the setting of increased myocardial stress, thus
providing a rationale for investigating activation of FLT3 in
the treatment of heart disease. The recent past provides an
exciting example of how to pursue this research question:
cardiotoxicity seen in patients with breast cancer treated with
the ErbB2 (HER2) receptor-targeted monoclonal antibody
trastuzumab has led to the discovery of critical HER2
signaling in the heart, thus forming a foundation for clinicalinvestigations of the HER2-receptor agonist neuregulin (8).
Today, neuregulin is being tested in Phase III clinical trials
for the treatment of chronic heart failure and exempliﬁes
a model of successful reverse translation research in cardio-
oncology (9).
The study by Pﬁster et al. (1) is the ﬁrst to show that
FLT3 activation may have an important role in regulating
and promoting cardiac cell survival. At present, it is unclear
whether and in what clinical setting the inhibition of this
kinase by novel FLT3-targeted oncological therapies may
lead to cardiac injury and cardiotoxicity. We await future
studies to build on the initial observations by Pﬁster et al.
and to discover how targeting FLT3 kinase can hurt or help
the heart kinome.
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